Benitec Biopharma (BNTC) Institutional Ownership → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free BNTC Stock Alerts $8.87 +0.97 (+12.28%) (As of 05/2/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Benitec Biopharma (NASDAQ:BNTC)CurrentInstitutional OwnershipPercentage52.19%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$571.67KNumber ofInstitutional Sellers(last 12 months)0 Get BNTC Insider Trade Alerts Want to know when executives and insiders are buying or selling Benitec Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data BNTC Institutional Buying and Selling by Quarter Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… Benitec Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2023Adage Capital Partners GP L.L.C.189,188$572K0.0%N/A7.419% 11/15/2022Empery Asset Management LP796,837$296K1.8%N/A2.848% 11/15/2022Cantor Fitzgerald L. P.133,805$50K0.0%N/A0.478% 11/14/2022Armistice Capital LLC1,555,039$578K0.0%N/A6.025% 11/14/2022Altium Capital Management LP658,796$245K0.1%N/A2.552% 11/9/2021BlackRock Inc.19,974$71K0.0%-16.4%0.244% Get the Latest News and Ratings for BNTC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter. 8/16/2021State Street Corp21,000$89K0.0%N/A0.267% 8/13/2021Renaissance Technologies LLC42,700$181K0.0%N/A0.544% 8/13/2021Northern Trust Corp11,813$50K0.0%N/A0.150% 8/13/2021Geode Capital Management LLC34,493$146K0.0%+20.8%0.439% 8/13/2021Vanguard Group Inc.74,773$318K0.0%+43.3%0.952% 8/11/2021 Bank of New York Mellon Corp14,932$63K0.0%-15.4%0.190% 7/31/2021Private Wealth Advisors LLC15,043$64K0.0%N/A0.192% 5/21/2021Citadel Advisors LLC23,253$120K0.0%N/A0.483% 5/19/2021Virtu Financial LLC22,520$116K0.0%+17.8%0.467% 5/18/2021Citadel Advisors LLC23,253$120K0.0%N/A0.483% 5/13/2021 Bank of New York Mellon Corp17,653$91K0.0%N/A0.366% 5/12/2021Geode Capital Management LLC28,560$147K0.0%N/A0.593% 4/14/2021WealthTrust Axiom LLC12,950$66K0.0%N/A0.269% 4/12/2021HighPoint Advisor Group LLC93,000$462K0.1%N/A1.930% 3/4/2021Hudson Bay Capital Management LP107,995$324K0.0%N/A2.241% 2/24/2021Virtu Financial LLC19,114$57K0.0%N/A0.397% 2/16/2021Warberg Asset Management LLC10,000$30K0.0%N/A0.903% 2/10/2021Renaissance Technologies LLC50,660$152K0.0%N/A4.572% 11/13/2020Morgan Stanley34,838$219K0.0%+18.7%3.144% 8/14/2020Sabby Management LLC11,863$94K0.0%-45.1%1.108% 5/15/2020Sabby Management LLC21,592$85K0.0%-81.7%2.016% 5/15/2020Morgan Stanley28,690$113K0.0%+82.1%2.679% (Data available from 1/1/2016 forward) BNTC Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of BNTC shares? During the previous two years, the following institutional investors and hedge funds held shares of Benitec Biopharma shares: Armistice Capital LLC ($578K), Adage Capital Partners GP L.L.C. ($572K), Empery Asset Management LP ($296K), and Altium Capital Management LP ($245K), Cantor Fitzgerald L. P. ($50K).Learn more on BNTC's institutional investors. What percentage of Benitec Biopharma stock is owned by institutional investors? 52.19% of Benitec Biopharma stock is owned by institutional investors. Learn more on BNTC's institutional investor holdings. Which institutional investors have been buying Benitec Biopharma stock? The following institutional investors have purchased Benitec Biopharma stock in the last 24 months: Armistice Capital LLC ($1.56M), Empery Asset Management LP ($796.84K), Altium Capital Management LP ($658.80K), Adage Capital Partners GP L.L.C. ($189.19K), and Cantor Fitzgerald L. P. ($133.81K). How much institutional buying is happening at Benitec Biopharma? Institutional investors have bought a total of 3,333,665 shares in the last 24 months. This purchase volume represents approximately $20.44M in transactions. Related Companies: ORGS Major Shareholders NERV Major Shareholders VBIV Major Shareholders HUGE Major Shareholders KALA Major Shareholders NRSN Major Shareholders FLGC Major Shareholders GLTO Major Shareholders TCRT Major Shareholders BIVI Major Shareholders This page (NASDAQ:BNTC) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
